Intravenous Thyroxine for Heart-Eligible Organ Donors

PHASE3CompletedINTERVENTIONAL
Enrollment

838

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

November 6, 2022

Study Completion Date

December 6, 2022

Conditions
Brain DeathHeart Failure
Interventions
DRUG

Thyroxine

Infusion prepared by mixing 500 μg of drug in 500-ml of normal saline (i.e. concentration of 1 μg/ml) and enclosing the bag in an opaque sleeve. Infusion started at 30 μg/hour (30 ml/hour) for twelve hours.

DRUG

Saline

The placebo will be a 500-ml bag of normal saline (without active drug) also enclosed in an opaque sleeve. This infusion will also be started at 30 ml/hour for twelve hours.

Trial Locations (14)

32751

OurLegacy, Maitland

44128

Lifebanc, Cleveland

52317

Iowa Donor Network, North Liberty

63110

Mid-America Transplant Services, St Louis

66205

Midwest Transplant Network, Westwood

70433

Louisiana Organ Procurement Agency, Covington

73132

LifeShare of Oklahoma, Oklahoma City

75231

Southwest Transplant Alliance, Dallas

78229

Texas Organ Sharing Alliance, San Antonio

80230

Donor Alliance, Denver

84107

DonorConnect, Murray

85013

Donor Network of Arizona, Phoenix

92108

Lifesharing, San Diego

98006

LifeCenter Northwest, Bellevue

All Listed Sponsors
collaborator

Mid-America Transplant

OTHER

lead

Washington University School of Medicine

OTHER

NCT04415658 - Intravenous Thyroxine for Heart-Eligible Organ Donors | Biotech Hunter | Biotech Hunter